A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine
- 1 March 2009
- Vol. 27 (13) , 1889-1897
- https://doi.org/10.1016/j.vaccine.2009.01.116
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given with or without Aluminum Hydroxide to Healthy Adults: Results of a Phase I–II Randomized Clinical TrialThe Journal of Infectious Diseases, 2008
- Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adultsVaccine, 2008
- Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibilityProceedings of the National Academy of Sciences, 2008
- Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trialVaccine, 2008
- Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza VaccinePLOS ONE, 2008
- Development and Evaluation of an Influenza Virus Subtype H7N2 Vaccine Candidate for Pandemic PreparednessClinical and Vaccine Immunology, 2007
- Comparison of the Influenza Virus-Specific Effector and Memory B-Cell Responses to Immunization of Children and Adults with Live Attenuated or Inactivated Influenza Virus VaccinesJournal of Virology, 2007
- Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and FerretsPLoS Medicine, 2006
- Strategies for mitigating an influenza pandemicNature, 2006
- Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic useVirus Research, 2004